Lisa Boselli
Overview
Explore the profile of Lisa Boselli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
524
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Flippot R, Teixeira M, Rey-Cardenas M, Carril-Ajuria L, Rainho L, Naoun N, et al.
J Immunother Cancer
. 2024 Apr;
12(4).
PMID: 38631710
Immunotherapy profoundly changed the landscape of cancer therapy by providing long-lasting responses in subsets of patients and is now the standard of care in several solid tumor types. However, immunotherapy...
2.
Naigeon M, Roulleaux Dugage M, Danlos F, Boselli L, Jouniaux J, de Oliveira C, et al.
Sci Adv
. 2023 Nov;
9(45):eadh0708.
PMID: 37939189
Circulating senescent CD8 T (Tsen) cells are characterized by a lack of proliferative capacities but retain cytotoxic activity and have been associated to resistance to immunotherapy in patients with advanced...
3.
Baldini C, Danlos F, Varga A, Texier M, Halse H, Mouraud S, et al.
J Exp Clin Cancer Res
. 2022 Jul;
41(1):217.
PMID: 35794623
Background: We aimed to determine the safety and efficacy of nintedanib, an oral anti-angiogenic tyrosine kinase inhibitor, in combination with pembrolizumab, an anti-PD1 immunotherapy, in patients with advanced solid tumors...
4.
Carril-Ajuria L, Desnoyer A, Meylan M, Dalban C, Naigeon M, Cassard L, et al.
J Immunother Cancer
. 2022 May;
10(5).
PMID: 35640928
Background: The phase II NIVOREN GETUG-AFU 26 study reported safety and efficacy of nivolumab in patients with metastatic clear cell renal cell carcinoma (m-ccRCC) in a 'real-world setting'. We conducted...
5.
Duchemann B, Naigeon M, Auclin E, Ferrara R, Cassard L, Jouniaux J, et al.
J Immunother Cancer
. 2022 Feb;
10(2).
PMID: 35131864
Background: Programmed cell death protein-1 (PD-1) expression has been associated with activation and exhaustion of both the CD4 and CD8 populations in advanced non-small cell lung cancer (aNSCLC). Nevertheless, the...
6.
Riudavets M, Naigeon M, Texier M, Dorta M, Barlesi F, Mazieres J, et al.
Lung Cancer
. 2021 Dec;
166:255-264.
PMID: 34953624
Introduction: A phase I open-label multicentre study was initiated to evaluate the association of tremelimumab with gefitinib in EGFR-mutant NSCLC patients who progressed after first-generation EGFR-TKI. Here we provide the...
7.
Duchemann B, Remon J, Naigeon M, Cassard L, Jouniaux J, Boselli L, et al.
Transl Lung Cancer Res
. 2021 Jul;
10(6):2937-2954.
PMID: 34295689
Immune checkpoint inhibitors (ICI) have been validated as an effective new treatment strategy in several tumoral types including lung cancer. This remarkable shift in the therapeutic paradigm is in large...
8.
Pasqualini C, Rubino J, Brard C, Cassard L, Andre N, Rondof W, et al.
Eur J Cancer
. 2021 Apr;
150:53-62.
PMID: 33892407
Purpose: AcSé-ESMART is a European multicentre, proof-of-concept multiarm phase I/II platform trial in paediatric patients with relapsed/refractory cancer. Arm G assessed the activity and safety of nivolumab in combination with...
9.
Duchemann B, Remon J, Naigeon M, Mezquita L, Ferrara R, Cassard L, et al.
Cancers (Basel)
. 2020 Dec;
12(12).
PMID: 33287347
Immune checkpoint inhibitors are now a cornerstone of treatment for non-small cell lung cancer (NSCLC). Tissue-based assays, such as Programmed cell death protein 1 (PD-L1) expression or mismatch repair deficiency/microsatellite...
10.
Ferrara R, Naigeon M, Auclin E, Duchemann B, Cassard L, Jouniaux J, et al.
Clin Cancer Res
. 2020 Sep;
27(2):492-503.
PMID: 32887723
Purpose: CD28, CD57, and KLRG1 have been previously identified as markers of T-cell immunosenescence. The impact of immunosenescence on anti-PD(L)-1 (ICI) or platinum-based chemotherapy (PCT) in patients with advanced non-small...